Aviva PLC Has $588,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Aviva PLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 11.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 28,160 shares of the biopharmaceutical company’s stock after selling 3,719 shares during the quarter. Aviva PLC’s holdings in Catalyst Pharmaceuticals were worth $588,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $65,000. KBC Group NV lifted its position in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent analyst reports. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird boosted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Trading Down 5.7 %

Shares of CPRX stock opened at $21.45 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16. The firm’s 50 day moving average is $22.65 and its 200-day moving average is $21.99. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 3.31 and a beta of 0.79.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.